With Myriad Genetics' announcement this week that it will acquire Crescendo Bioscience for $270 million in cash, clinical proteomics has scored what is perhaps its most significant endorsement to date.

The field has notched a number of advances in recent years, including product launches, US Food and Drug Administration clearances, and the increasing adoption of mass spec as a clinical tool. In terms of actual profits, however, proteomic diagnostics have, generally speaking, underwhelmed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.